Annovis Bio, Inc.

Annovis Bio is a clinical-stage biotechnology company focused on developing therapeutic candidates for neurodegenerative diseases. The company operates a drug platform designed to address protein accumulation implicated in neuronal damage and cognitive decline. Based in Malvern, Pennsylvania, Annovis was incorporated in 2008 and operates with a small team of eight full-time employees.

The company's primary asset is Buntanetap, its lead product candidate currently in phase 2/3 development for Alzheimer's disease and phase 3 trials for Parkinson's disease, with phase 2 studies underway for Lewy body dementia. Annovis also develops ANVS405, which is progressing through phase 2 and 3 clinical trials for traumatic brain injury and stroke, and ANVS301, which completed phase 1 testing for advanced Alzheimer's disease and dementia. The company has not disclosed revenue streams, as it remains in clinical development stages without approved marketed products.

Annovis is listed on the NYSE and operates primarily in the United States. With a modest employee base and clinical-stage portfolio, the company's current business model centers on advancing drug candidates through regulatory development pathways rather than generating commercial revenue.